



Auxellence Announces Mr. C.K. Cheung Appointed as Advisor

VANCOUVER, BC, Friday September 9th, 2016 – Auxellence Health Corporation (CSE: AID, OTCQB: AXHLF) (“Auxellence” or the “Company”) is pleased to announce the appointment of Mr. Chun Kwok (C.K.) Cheung as an advisor to the board.

Mr. C.K. Cheung has served in the capacity of a forex head trader in an investment bank before becoming an owner in a forex brokerage firm in Taiwan, handling transactions with numerous international banks. He went on to be in charge of Far East District Forex and Currency Exchanges Platform in China, and is currently serving as an Executive Director for the China Investment Trust Fund.

“With the rebranding of the company to focus on the telehealth and home monitoring services platform as well as looking at initiatives in the Asia Pacific region, we feel Mr. Cheung is uniquely qualified with many strong connections to assist with our efforts at all levels. We welcome his input and appreciate his willingness to commit his time to assist the Company, and advise the board”, said Sydney Au, Chairman and CEO.

Contact:

Sydney Au, CEO

Auxellence Health Corporation

Email: ceo@auxellence.com

Phone: (604) 780-3311

Website: <http://www.auxellence.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/auxellence-health-corporation>

About Auxellence Health Corporation (CSE: AID, OTCQB: AXHLF)

Auxellence was founded in 2013 to provide online services for resolving common health problems.

The company offers a physiologically interactive computing platform that integrates medical devices and artificial intelligence applications into a fully automated, personal health management system for hypertension, arrhythmia, diabetes, and obesity.

The current focus is on the normalization of cardiometabolic power in terms of blood pressure, blood glucose, and body weight – and the monitoring of the physiological response to medical solicitations, mainly medication, diet, exercise, and lifestyle changes.

About TULIP™

The TULIP™ system is an online self-service intended for adults interested in normalizing blood pressure, heart rate and rhythm, blood glucose, and body weight. Measurement procedures, conditioning protocols, and session schedules are prescribed automatically from data acquired by the user's TULIP™ device – a



AUXELLE

Health Corporation

blood pressure monitor with interactive protocols that can feed medical records and expert systems useful in testing, tracking and treating common health conditions.

The Tulip™ medical device has received Health Canada and CE Mark certifications.

Disclaimers – Forward Looking Statements

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators which is posted on www.sedar.com, and on <http://thecse.com/en/listings/technology/auxellence-health-corporation>.

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.